BRPI0514893A - quinazolinas úteis como moduladores de canais de ìon - Google Patents
quinazolinas úteis como moduladores de canais de ìonInfo
- Publication number
- BRPI0514893A BRPI0514893A BRPI0514893-6A BRPI0514893A BRPI0514893A BR PI0514893 A BRPI0514893 A BR PI0514893A BR PI0514893 A BRPI0514893 A BR PI0514893A BR PI0514893 A BRPI0514893 A BR PI0514893A
- Authority
- BR
- Brazil
- Prior art keywords
- ion channel
- channel modulators
- useful
- quinazolines useful
- quinazolines
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Anesthesiology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
QUINAZOLINAS úTEIS COMO MODULADORES DE CANAIS DE ìON. A presente invenção refere-se a compostos úteis como inibidores de canais de sódio fechados por voltagem. A invenção também fornece composições que compreendem os compostos da invenção e métodos de empregar as composições no tratamento de vários distúrbios.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60724504P | 2004-09-02 | 2004-09-02 | |
US60703604P | 2004-09-02 | 2004-09-02 | |
US60715004P | 2004-09-02 | 2004-09-02 | |
US60703704P | 2004-09-02 | 2004-09-02 | |
US60703304P | 2004-09-02 | 2004-09-02 | |
PCT/US2005/031146 WO2006028904A1 (en) | 2004-09-02 | 2005-08-31 | Quinazolines useful as modulators of ion channels |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0514893A true BRPI0514893A (pt) | 2007-11-27 |
Family
ID=35517001
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0514893-6A BRPI0514893A (pt) | 2004-09-02 | 2005-08-31 | quinazolinas úteis como moduladores de canais de ìon |
Country Status (19)
Country | Link |
---|---|
EP (1) | EP1784393B1 (pt) |
JP (1) | JP5014994B2 (pt) |
KR (1) | KR20070057914A (pt) |
CN (1) | CN101068794B (pt) |
AT (1) | ATE435214T1 (pt) |
AU (1) | AU2005282761B2 (pt) |
BR (1) | BRPI0514893A (pt) |
CA (1) | CA2578739A1 (pt) |
DE (1) | DE602005015231D1 (pt) |
ES (1) | ES2327945T4 (pt) |
HK (1) | HK1104544A1 (pt) |
IL (1) | IL181700A0 (pt) |
MA (1) | MA28909B1 (pt) |
MX (1) | MX2007002582A (pt) |
NO (1) | NO20071742L (pt) |
NZ (1) | NZ589252A (pt) |
RU (1) | RU2440991C2 (pt) |
WO (1) | WO2006028904A1 (pt) |
ZA (1) | ZA200702375B (pt) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005097803A1 (ja) | 2004-04-09 | 2005-10-20 | Chugai Seiyaku Kabushiki Kaisha | 新規水溶性プロドラッグ |
US7928107B2 (en) | 2004-09-02 | 2011-04-19 | Vertex Pharmaceuticals Incorporated | Quinazolines useful as modulators of ion channels |
TW200744603A (en) | 2005-08-22 | 2007-12-16 | Chugai Pharmaceutical Co Ltd | Novel anticancer concomitant drug |
AU2006305169A1 (en) * | 2005-10-19 | 2007-04-26 | Chugai Seiyaku Kabushiki Kaisha | Preventive or therapeutic agents for pancreatic cancer, ovarian cancer, or liver cancer comprising a novel water-soluble prodrug |
KR20080073749A (ko) * | 2005-11-14 | 2008-08-11 | 버텍스 파마슈티칼스 인코포레이티드 | 전압 개폐 이온 채널 조절제로서 유용한 퀴나졸린 |
WO2007071055A1 (en) * | 2005-12-21 | 2007-06-28 | Painceptor Pharma Corporation | Compositions and methods for modulating gated ion channels |
US8883781B2 (en) | 2006-06-12 | 2014-11-11 | Vertex Pharmaceuticals Incorporated | Thienopyrimidines useful as modulators of ion channels |
AU2007328336B2 (en) | 2006-12-01 | 2014-04-17 | President And Fellows Of Harvard College | Compounds and methods for enzyme-mediated tumor imaging and therapy |
WO2008147864A2 (en) * | 2007-05-22 | 2008-12-04 | Xenon Pharmaceuticals Inc. | Methods of using piperazine compounds in treating sodium channel-mediated diseases or conditions |
WO2008157500A1 (en) * | 2007-06-17 | 2008-12-24 | Kalypsys, Inc. | Aminoquinazoline cannabinoid receptor modulators for treatment of disease |
WO2012046132A1 (en) | 2010-10-05 | 2012-04-12 | Purdue Pharma L.P. | Quinazoline compounds as sodium channel blockers |
EP2640366A2 (en) | 2010-11-15 | 2013-09-25 | Exelixis, Inc. | Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture |
EP2670722B1 (en) | 2011-01-31 | 2016-10-12 | Council of Scientific & Industrial Research | Chiral 1-(4-methylphenylmethyl)-5-oxo-{n-[(3-t-butoxycarbonyl-aminomethyl)]-piperidin-1-yl}-pyrrolidine-2-carboxamides as inhibitors of collagen induced platelet activation and adhesion |
PL2723710T3 (pl) | 2011-06-27 | 2017-02-28 | Newron Pharmaceuticals S.P.A. | Fluorowane pochodne aryloalkiloaminokarboksyamidowe |
CN109153652B (zh) * | 2016-04-01 | 2021-07-27 | 上海瑛派药业有限公司 | 1-(芳基甲基)喹唑啉-2,4(1h,3h)-二酮的制备工艺 |
IL272089B2 (en) | 2017-08-09 | 2023-09-01 | Denali Therapeutics Inc | Compounds, preparations and methods |
EP3768660A1 (en) * | 2018-03-23 | 2021-01-27 | Denali Therapeutics Inc. | Modulators of eukaryotic initiation factor 2 |
JP2022520236A (ja) | 2019-02-13 | 2022-03-29 | デナリ セラピューティクス インコーポレイテッド | 化合物、組成物、及び、方法 |
CA3153302A1 (en) * | 2019-10-10 | 2021-04-15 | Carmen ALMANSA-ROSALES | Homopiperazinyl and homopiperidinyl quinazolin-4(3h)-one derivatives having multimodal activity against pain |
EP4069691A1 (en) | 2019-12-06 | 2022-10-12 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofurans as modulators of sodium channels |
AU2022284886A1 (en) | 2021-06-04 | 2023-11-30 | Vertex Pharmaceuticals Incorporated | N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH083144A (ja) * | 1994-06-21 | 1996-01-09 | Chugai Pharmaceut Co Ltd | キナゾリン及びキノリン誘導体 |
EP1230225A2 (en) * | 1999-11-01 | 2002-08-14 | Eli Lilly And Company | Pharmaceutically active 4-substituted pyrimidine derivatives |
SE0004055D0 (sv) * | 2000-11-06 | 2000-11-06 | Astrazeneca Ab | N-type calcium channel antagonists for the treatment of pain |
SE0004054D0 (sv) * | 2000-11-06 | 2000-11-06 | Astrazeneca Ab | N-type calcium channel antagonists for the treatment of pain |
CL2004000409A1 (es) * | 2003-03-03 | 2005-01-07 | Vertex Pharma | Compuestos derivados de 2-(cilo sustituido)-1-(amino u oxi sustituido)-quinazolina, inhibidores de canales ionicos de sodio y calcio dependientes de voltaje; composicion farmaceutica; y uso del compuesto en el tratamiento de dolor agudo, cronico, neu |
JP5112297B2 (ja) * | 2005-05-20 | 2013-01-09 | バーテックス ファーマシューティカルズ インコーポレイテッド | イオンチャネルのモジュレーターとして有用なキノリン誘導体 |
-
2005
- 2005-08-31 AU AU2005282761A patent/AU2005282761B2/en not_active Ceased
- 2005-08-31 NZ NZ589252A patent/NZ589252A/en not_active IP Right Cessation
- 2005-08-31 DE DE602005015231T patent/DE602005015231D1/de active Active
- 2005-08-31 AT AT05807734T patent/ATE435214T1/de active
- 2005-08-31 JP JP2007530356A patent/JP5014994B2/ja not_active Expired - Fee Related
- 2005-08-31 ES ES05807734T patent/ES2327945T4/es active Active
- 2005-08-31 BR BRPI0514893-6A patent/BRPI0514893A/pt not_active IP Right Cessation
- 2005-08-31 CA CA002578739A patent/CA2578739A1/en not_active Abandoned
- 2005-08-31 KR KR1020077007601A patent/KR20070057914A/ko not_active Application Discontinuation
- 2005-08-31 ZA ZA200702375A patent/ZA200702375B/xx unknown
- 2005-08-31 EP EP05807734A patent/EP1784393B1/en active Active
- 2005-08-31 MX MX2007002582A patent/MX2007002582A/es unknown
- 2005-08-31 CN CN2005800374969A patent/CN101068794B/zh not_active Expired - Fee Related
- 2005-08-31 RU RU2007111897/04A patent/RU2440991C2/ru not_active IP Right Cessation
- 2005-08-31 WO PCT/US2005/031146 patent/WO2006028904A1/en active Application Filing
-
2007
- 2007-03-02 MA MA29735A patent/MA28909B1/fr unknown
- 2007-03-04 IL IL181700A patent/IL181700A0/en unknown
- 2007-04-02 NO NO20071742A patent/NO20071742L/no not_active Application Discontinuation
- 2007-09-07 HK HK07109785.3A patent/HK1104544A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
CN101068794A (zh) | 2007-11-07 |
CN101068794B (zh) | 2012-12-19 |
CA2578739A1 (en) | 2006-03-16 |
JP2008511670A (ja) | 2008-04-17 |
DE602005015231D1 (de) | 2009-08-13 |
KR20070057914A (ko) | 2007-06-07 |
WO2006028904A9 (en) | 2006-06-22 |
ZA200702375B (en) | 2009-03-25 |
EP1784393A1 (en) | 2007-05-16 |
AU2005282761A1 (en) | 2006-03-16 |
NZ589252A (en) | 2012-06-29 |
NO20071742L (no) | 2007-04-02 |
ES2327945T4 (es) | 2010-07-02 |
EP1784393B1 (en) | 2009-07-01 |
JP5014994B2 (ja) | 2012-08-29 |
RU2440991C2 (ru) | 2012-01-27 |
RU2007111897A (ru) | 2008-10-10 |
ATE435214T1 (de) | 2009-07-15 |
AU2005282761B2 (en) | 2012-02-02 |
MX2007002582A (es) | 2008-01-14 |
MA28909B1 (fr) | 2007-10-01 |
HK1104544A1 (en) | 2008-01-18 |
WO2006028904A1 (en) | 2006-03-16 |
ES2327945T3 (es) | 2009-11-05 |
IL181700A0 (en) | 2007-07-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0514893A (pt) | quinazolinas úteis como moduladores de canais de ìon | |
ATE527251T1 (de) | Bicyclische derivate als modulatoren von ionenkanälen | |
NO20090157L (no) | Tienpyrimidiner anvendelige som modulatorer av ionekanaler | |
TW200519094A (en) | Pyrimidines useful as modulators of voltage-gated ion channels | |
TW200740803A (en) | Heterocyclic derivatives as modulators of ion channels | |
HUS2100051I1 (hu) | Kompozíciók és eljárások sejtproliferációs rendellenességek kezelésére | |
MX2010003864A (es) | Amidas utiles como inhibidores de canales de sodio dependientes de voltaje. | |
MX2010003865A (es) | Aril amidas utiles como inhibidores de canales de sodio dependientes de voltaje. | |
MX2010003866A (es) | Heteroaril amidas utiles como inhibidores de canales de sodio dependientes de voltaje. | |
NO20054546L (no) | Kinazoliner anvendelige som modulatorer av ionekanaler | |
ATE540036T1 (de) | Heterocyclische derivate als ionenkanalmodulatoren | |
WO2007058989A3 (en) | Quinazolines useful as modulators of voltage gated ion channels | |
NO20080141L (no) | Indanderivater som modulatorer av ionekanaler | |
MY160041A (en) | Compositions and methods for treating parasitic infections | |
WO2006050476A3 (en) | Pyrimidine derivatives as ion channel modulators and methods of use | |
MX2010003009A (es) | Piridil sulfonamidas como moduladores de canales ionicos. | |
WO2008147797A3 (en) | Ion channel modulators and methods of use | |
ZA200803704B (en) | Biphenyl derivatives as modulators of voltage gated ion channels | |
AU2006287480A8 (en) | Bicyclic derivatives as modulators of voltage gated ion channels | |
BRPI0511124A (pt) | pró-drogas de inibidores de erk proteìna cinase de pirrolilpirimidina | |
ATE425982T1 (de) | Thienopyrimidin-derivate als kaliumkanal- inhibitoren | |
ATE389651T1 (de) | Als inhibitoren von c-met geeignete pyrrolzusammensetzungen | |
MX2009002842A (es) | Inhibidores heterociclicos de c-met y usos de los mismos. | |
DE602008005786D1 (de) | C-met-proteinkinasehemmer | |
WO2006130493A8 (en) | Heterocycles useful as modulators of ion channels |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012. |